← Eichor
Condition: Pd 1 Inhibitors Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Pd 1 Inhibitors

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breas
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07394387Clinical Study of Fasudil Hydrochloride and PD1 Inhibitor Combined With Androgen Deprivation in Neoadjuvant Therapy of P
Phase 2/Phase 3 · 1 location(s) · baotai Liang · NCT06861192HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT06333561Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer
Phase 2 · 1 location(s) · Fudan University · NCT06455124A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plu
Phase 1/Phase 2 · 1 location(s) · Yinghua Xu · NCT07495215Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic On
Phase 2 · 2 location(s) · Fudan University · NCT05281003BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
Phase 2 · 33 location(s) · SCRI Development Innovations, LLC · NCT06773910Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC
Phase 2 · 1 location(s) · Beijing Tongren Hospital · NCT06100497Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer
Phase 2 · 1 location(s) · Tianjin Medical University Second Hospital · NCT07125547PD-1 Inhibitors Combined With Local Therapy at Different Timings in Oligometastatic ESCC
Phase N/A · 1 location(s) · Fudan University · NCT07697859Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer
Phase 2 · 1 location(s) · Jinhua Central Hospital · NCT06204094Electroacupuncture Combined With PD-1 Inhibitor for ECOG2 Advanced NSCLC
NA · 1 location(s) · Kong Fanming · NCT07239661Intranasal WSK-IM05 Vaccine Plus Tislelizumab as Neoadjuvant Therapy for HPV+ OPSCC
Phase 1 · 1 location(s) · West China Hospital · NCT07565740An Observational Clinical Study of Stereotactic Radiotherapy for Advanced Non-Small Cell Lung Cancer With Stable Disease
Phase N/A · 1 location(s) · Xinqiao Hospital of Chongqing · NCT05486650Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody
Phase N/A · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT05392413Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer
Phase 2 · 1 location(s) · Women's Hospital School Of Medicine Zhejiang University · NCT06561308Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer
Phase 1/Phase 2 · 1 location(s) · Coordination Pharmaceuticals, Inc. · NCT05838729Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophagea
Phase 2 · 1 location(s) · Second Affiliated Hospital of Zunyi Medical University · NCT07559045Omega-3 Fatty Acids With PD-1 Inhibitors in Advanced Esophageal Cancer
NA · 1 location(s) · Fudan University · NCT07272382Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced
Phase 2 · 6 location(s) · Sichuan University · NCT06121505Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment with or Without Sonrotoclax for Patients with Richter Tr
Phase 2 · 11 location(s) · German CLL Study Group · NCT04271956PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer
Phase 3 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06086457Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors
Phase 1 · 1 location(s) · HC Biopharma Inc. · NCT06963814WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07330050A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM
Phase 2 · 1 location(s) · Shanghai 6th People's Hospital · NCT06590259CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Canc
Phase 1 · 1 location(s) · Washington University School of Medicine · NCT05187182PD-1 Inhibitors Maintenance for cHL Post-autoHCT
Phase 2 · 4 location(s) · St. Petersburg State Pavlov Medical University · NCT06812858Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Can
Phase 2 · 6 location(s) · Shanghai Pulmonary Hospital, Shanghai, China · NCT05053802Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer
Phase 2 · 1 location(s) · Fudan University · NCT06039631Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carc
Phase 2 · 1 location(s) · Jiangxi Provincial Cancer Hospital · NCT07277764
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.